stockportfolio.pro
CRISPR Therapeutics AG (CRSP)
Healthcare · Biotechnology · NasdaqGM
CRISPR Therapeutics AG revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.16M | $41.00M | $3.12M | $289.59M | $719,000 | $914.96M | $436,000 | $370.00M | $35.00M | $3.51M |
| Gross profit | — | — | — | — | — | — | $-109.81M | $239.75M | $-85.67M | $-213.48M |
| Net income | $-23.18M | $-68.36M | $-164.98M | $66.86M | $-348.87M | $377.66M | $-650.17M | $-153.61M | $-366.25M | $-581.60M |
| Net margin | -448.8% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.3% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
Source: CRISPR Therapeutics AG SEC filings (10-K). 12 years of history available in the interactive view.
Explore 12 years of CRISPR Therapeutics AG financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CRSP in your portfolio →
CRISPR Therapeutics AG financial history by metric
About CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
CRISPR Therapeutics AG — frequently asked questions
What is CRISPR Therapeutics AG's revenue?
CRISPR Therapeutics AG (CRSP) reported revenue of $3.51M for fiscal year 2025, down 90.0% from the prior year, according to its SEC filings.
Is CRISPR Therapeutics AG profitable?
No — CRSP reported a net loss of $-581.60M in fiscal 2025.
What is CRSP's P/E ratio?
CRISPR Therapeutics AG trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is CRISPR Therapeutics AG growing?
CRSP's revenue grew at roughly 37.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does CRISPR Therapeutics AG have?
As of fiscal year 2025, CRSP carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is CRISPR Therapeutics AG's gross margin?
CRSP's gross margin was -6082.1% in fiscal 2025 — gross profit of $-213.48M on revenue of $3.51M.
What is CRISPR Therapeutics AG's market cap?
CRISPR Therapeutics AG (CRSP) has a market capitalization of about $4.93B, based on the latest data in our nightly-refreshed cache.
When does CRISPR Therapeutics AG's fiscal year end?
CRSP's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from CRISPR Therapeutics AG's official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.